On Tuesday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) was -3.90% drop from the session before settling in for the closing price of $12.83. A 52-week range for SPRY has been $7.55 – $18.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 59377.90%. When this article was written, the company’s average yearly earnings per share was at -1764.10%. With a float of $56.04 million, this company’s outstanding shares have now reached $97.95 million.
The extent of productivity of a business whose workforce counts for 160 workers is very important to gauge. In terms of profitability, gross margin is 98.87%, operating margin of -3.46%, and the pretax margin is 9.29%.
ARS Pharmaceuticals Inc (SPRY) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ARS Pharmaceuticals Inc stocks. The insider ownership of ARS Pharmaceuticals Inc is 42.88%, while institutional ownership is 50.12%. The most recent insider transaction that took place on Apr 07 ’25, was worth 615,075. In this transaction Director of this company sold 50,002 shares at a rate of $12.30, taking the stock ownership to the 210,346 shares. Before that another transaction happened on Apr 07 ’25, when Company’s Director proposed sale 50,002 for $12.30, making the entire transaction worth $615,051.
ARS Pharmaceuticals Inc (SPRY) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1764.10% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
You can see what ARS Pharmaceuticals Inc (SPRY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.57. Likewise, its price to free cash flow for the trailing twelve months is 93.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.08, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
The latest stats from [ARS Pharmaceuticals Inc, SPRY] show that its last 5-days average volume of 2.28 million was superior to 1.62 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 41.99%. Additionally, its Average True Range was 1.01.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 29.49%, which indicates a significant increase from 14.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 115.19% in the past 14 days, which was higher than the 70.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.06, while its 200-day Moving Average is $12.53. Now, the first resistance to watch is $13.16. This is followed by the second major resistance level at $13.98. The third major resistance level sits at $14.55. If the price goes on to break the first support level at $11.77, it is likely to go to the next support level at $11.20. Assuming the price breaks the second support level, the third support level stands at $10.38.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are 98,120K outstanding shares of the company, which has a market capitalization of 1.21 billion. As of now, sales total 89,150 K while income totals 8,000 K. Its latest quarter income was 86,580 K while its last quarter net income were 49,930 K.
